Bita Shahrami

Dr. Bita Shahrami

Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, Tehrān, Iran
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2022 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Closed access
BSBita Shahrami
Bita Shahrami
AFAida Sefidani Forough
Aida Sefidani Forough
FNFarhad Najmeddin
Farhad Najmeddin
EHElham Hadidi
Elham Hadidi
STSomayeh Toomaj
Somayeh Toomaj
KSKourosh Sadeghi
Kourosh Sadeghi

12 March 2021 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Open access
PDF file
BSBita Shahrami
Bita Shahrami
MSMaryam Sharif
Maryam Sharif
AFAida Sefidani Forough
Aida Sefidani Forough
FNFarhad Najmeddin
Farhad Najmeddin
AAAmir Ahmad Arabzadeh
Amir Ahmad Arabzadeh
MMMojtaba Mojtahedzadeh
Mojtaba Mojtahedzadeh
What is known and objective Sepsis is a life‐threatening organ dysfunction associated with a high rate of morbidity and mortality. Appropriate antibiotic therapy remains the cornerstone of sepsis and septic shock management. Comment Although the early initiation of antimicrobial agents in the treatment of sepsis is widely acknowledged, the selection and adjustment to optimal dosage can be equally important. Since significant pathophysiological changes in the critically ill patients lead to altered pharmacokinetics of antibiotics, early consideration of pharmacokinetic/pharmacodynamic (PK/PD) properties is necessary for optimal antibiotic dosing in sepsis and should be integrated in practice. What is new and conclusion Where possible, an individualized antibiotic dosing approach through the application of therapeutic drug monitoring (TDM) service should replace the conventional dosing in critically ill patients with sepsis. Finally, antimicrobial stewardship can help improve clinical outcomes.

11 December 2019 in Advanced Pharmaceutical Bulletin
Verified
Journal Article
Open access
BSBita Shahrami
Bita Shahrami
FNFarhad Najmeddin
Farhad Najmeddin
Mohammadreza RouiniMohammadreza Rouini
Mohammadreza Rouini
ANAtabak Najafi
Atabak Najafi
KSKourosh Sadeghi
Kourosh Sadeghi
MMMojtaba Mojtahedzadeh
Mojtaba Mojtahedzadeh
Purpose: Although the current widespread use of amikacin is in intra-abdominal sepsis treatment, its pharmacokinetic changes in the present setting are not yet well known. This study was aimed to evaluate the amikacin pharmacokinetic profile in critically ill patients with intraabdominal sepsis compared to pneumosepsis. Methods: Adult septic patients received amikacin therapy were studied. Patients with intraabdominal sepsis were enrolled in group 1 (n=16), and patients with pneumosepsis were enrolled in group 2 (n=13). The amikacin serum concentrations were evaluated in the first, second, fourth and sixth hours after initiating 30-minute infusion. The pharmacokinetic parameters were calculated for each patient. Results: There was no significant difference in the volume of distribution between the two groups (0.33±0.08 vs. 0.28±0.10 L/kg, P=0.193). The amikacin clearance was significantly lower in group 1 compared to group 2 (58.5±21.7 vs. 83.9±37.0 mL/min, P=0.029). There was no significant correlation between amikacin clearance and creatinine clearance estimated by Cockcroft-Gault formula in all patients (P=0.206). The half-life was significantly longer in group 1 compared to group 2 (5.3±2.8 vs. 3.4±3.2 hours, P=0.015). Conclusion: Pathophysiologic changes following intra-abdominal sepsis can affect amikacin pharmacokinetics behavior. The clearance and half-life may change, but the alteration of the volume of distribution is not significantly different in comparison with pneumosepsis. Further studies are required to evaluate the pharmacokinetic variables of amikacin in critically ill patients with intra-abdominal sepsis.

24 May 2023 in Case Reports in Oncology
Verified
Journal Article
Open access
PDF file
SHShima Heidari
Shima Heidari
MPMahsa Panahishokouh
Mahsa Panahishokouh
DBDavoud Babakhani
Davoud Babakhani
SASohrab Aghabeigi
Sohrab Aghabeigi
MVMohammad Vaezi
Mohammad Vaezi
BSBita Shahrami
Bita Shahrami
Vincristine (VCR) as a key drug for the treatment of acute lymphoblastic leukemia (ALL) is associated with neurotoxicity. We present a young man with a history of controlled childhood seizures who was diagnosed with pre-B-cell ALL and developed generalized tonic-clonic seizures following the Cancer and Leukemia Group B (CALGB) 8811 regimen. The patient also received oral itraconazole to prevent fungal infection initiated by chemotherapy. Possible causes of seizure, including electrolyte abnormalities, hypoglycemia, central nervous system infection or inflammation, were ruled out. According to the Naranjo Adverse Drug Reaction Scale, the patient’s seizure had been attributed to VCR, possibly secondary to concomitant use of itraconazole and doxorubicin. The patient successfully recovered after discontinuation of VCR and supportive care. Clinicians should be aware of the possibility of vincristine-induced seizure in adult patients, especially with the concomitant use of drugs known to have potential drug-drug interactions.

24 December 2020 in Critical Care Research and Practice
Verified
Journal Article
Open access
BSBita Shahrami
Bita Shahrami
FNFarhad Najmeddin
Farhad Najmeddin
SGSaeideh Ghaffari
Saeideh Ghaffari
ANAtabak Najafi
Atabak Najafi
Mohammadreza RouiniMohammadreza Rouini
Mohammadreza Rouini
MMMojtaba Mojtahedzadeh
Mojtaba Mojtahedzadeh
Area under the Curve-Based Dosing of Vancomycin in Critically Ill Patients Using 6-Hour Urine Creatinine Clearance Measurement: Background. The area under the curve- (AUC-) guided vancomycin dosing is the best strategy for individualized therapy in critical illnesses. Since AUC can be calculated directly using drug clearance (CLvan), any parameter estimating CLvan will be able to achieve the goal of 24-hour AUC (AUC24 h). The present study was aimed to determine CLvan based on 6-hour urine creatinine clearance measurement in critically ill patients with normal renal function. Method. 23 adult critically ill patients with an estimated glomerular filtration rate (eGFR) ≥60 mL/min who received vancomycin infusion were enrolled in this pilot study. Vancomycin pharmacokinetic parameters were determined for each patient using serum concentration data and a one-compartment model provided by MONOLIX software using stochastic approximation expectation-maximization (SAEM) algorithm. Correlation of CLvan with the measured creatinine clearance in 6-hour urine collection (CL6 h) and estimated creatinine clearance by the Cockcroft–Gault formula (CLCG) was investigated. Results. Data analysis revealed that CL6 h had a stronger correlation with CLvan rather than CLCG (r = 0.823 vs. 0.594; vs. 0.003). The relationship between CLvan and CL6 h was utilized to develop the following equation for estimating CLvan: CLvan (mL/min) = ─137.4 + CL6 h (mL/min) + 2.5 IBW (kg) (R2 = 0.826, ). Regarding the described model, the following equation can be used to calculate the empirical dose of vancomycin for achieving the therapeutic goals in critically ill patients without renal impairment: total daily dose of vancomycin (mg) = (─137.4CL6-h (mL/min) + 2.5 IBW (kg)) × 0.06 AUC24 h (mg.hr/L). Conclusion. For AUC estimation, CLvan can be obtained by collecting urine in a 6-hour period with good approximation in critically ill patients with normal renal function.

2 September 2024 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
SZSogol Zarrabi
Sogol Zarrabi
EHElham Hosseini
Elham Hosseini
KSKourosh Sadeghi
Kourosh Sadeghi
MVMohammad Vaezi
Mohammad Vaezi
BSBita Shahrami
Bita Shahrami
Introduction: Patients with hematologic malignancies often receive multiple medications, leading to potential drug-drug interactions (DDIs). Identifying and managing these DDIs is crucial for ensuring patient safety and effective care. This study aimed to identify and describe DDIs and associated factors in hematologic malignancy patients. Methods: This prospective interventional study was conducted at a referral center and included hospitalized patients with hematologic malignancies who were receiving at least four concurrent medications. A pharmacist initially compiled a comprehensive list of all medications through patient interviews and medication reviews, and subsequently, identified and categorized potential DDIs using the Lexi-interact ® and Micromedex ® databases. The clinical pharmacist then evaluated the clinical impact of the identified DDIs in every individual patient and provided appropriate interventions to resolve them. Results: A total of 200 patients met the inclusion criteria for the study, with 1281 DDIs identified across 337 distinct types. The majority of identified DDIs exhibited major severity (52.1%) and pharmacokinetic mechanisms (50.3%), with an unspecified onset (79.4%) and fair evidence (67%). Of the identified DDIs, 81.1% were considered clinically significant, prompting 1059 pharmacotherapy interventions by the clinical pharmacist. Additionally, a significant relationship was observed between the number of drugs used during hospitalization and the occurrence of DDIs (P < 0.001, r = 0.633). Conclusion: DDIs are highly prevalent among hospitalized patients with hematologic malignancies, with their occurrence increasing alongside the number of medications administrated. The intervention of a clinical pharmacist is crucial to evaluate the clinical impact of these DDIs and implement effective interventions for their management.